Prakt. lékáren. 2014; 10(3): 90-94

Adverse effects and drug interactions of nonsteroidal anti-inflammatory drugs and their management

Martin Doseděl
Katedra sociální a klinické farmacie, FaF Hradec Králové

as seen by a pharmacist

Nonsteroidal anti-inflammatory drugs are encountered by pharmacists in their practice on a daily basis. These drugs, however, have

a number of adverse effects and a relatively large interaction potential. Gastrointestinal tract injury, hepatopathy, nephropathy,

and increased cardiovascular risk are among the most serious adverse effects. Drug interactions usually potentiate these risks. The article

deals with particular adverse effects of nonsteroidal anti-inflammatory drugs and also describes the quantitative difference in the rates

of these risks among the individual agents from the class of nonsteroidal anti-inflammatory drugs. The most common clinically significant

drug interactions of nonsteroidal anti-inflammatory drugs are presented in a table. Two case reports are included to demonstrate

the management of the risks of nonsteroidal anti-inflammatory drugs.

Keywords: nonsteroidal anti-inflammatory drugs, adverse effects, drug interactions, pharmaceutical care

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doseděl M. Adverse effects and drug interactions of nonsteroidal anti-inflammatory drugs and their management. Praktické lékárenství. 2014;10(3):90-94.
Download citation

References

  1. Walker R, Whittlesea C. Clinical Pharmacy and Therapeutics. 4th ed. London (UK) Elsevier; 2007: 900 p.
  2. Slíva J, Votava M. Farmakologie. Praha (CZ) Triton; 2011: 394 p.
  3. Státní ústav pro kontrolu léčiv ČR. Databáze léků. [Internet]. Praha (CZ) [cited 2014 Apr 2]. Available from: http://www.sukl.cz/modules/medication/search.php.
  4. Aktualizovaný informační systém léčivých přípravků (AISLP), verze 2013.2 pro MS Windows.
  5. Lukáš M. Gastropatie a enteropatie z nesteroidních antirevmatik. Interní med. 2006; 11: 489-492.
  6. Ng SC, Chan FK. NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol. 2010; 26(6): 611-617. Go to original source... Go to PubMed...
  7. Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf. 2009; 1: 47-71. Go to original source... Go to PubMed...
  8. Rostom A, Muir K, Dubé C, Jolicoeur E, Boucher M, Joyce J, Tugwell P, Wells GW. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007; 5(7): 818-828. Go to original source... Go to PubMed...
  9. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010; 62(6): 1592-1601. Go to original source... Go to PubMed...
  10. Micromedex(R) Healthcare Series. [Internet]. Thomson Reuters (Healthcare) Inc., Greenwood Village [cited 2013 May 29]. Available from: http://www.thomsonhc.com.
  11. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003; 327(7405): 18-22. Go to original source... Go to PubMed...
  12. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010; 16(45): 5651-5661. Go to original source... Go to PubMed...
  13. Aktualizovaný informační systém léčivých přípravků (AISLP), verze 2013.2, pro MS Windows. SPC Aulin(R), Medicom International s.r.o., Brno, Česká republika.
  14. Slíva J. Hepatotoxicita léčiv se zaměřením na paracetamol a NSA. Med. Praxi 2013; 10(1): 26-17.
  15. Varga Z, Kristelová V, Kriška M. Kardiovaskulárne riziko nesteroidových antiflogistík - klinický dopad a možné mechanizmy. Klin Farmakol Farm. 2011; 25(3): 131-136.
  16. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086. Go to original source... Go to PubMed...
  17. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum. 2002; 32(3 Suppl 1): 33-42. Go to original source... Go to PubMed...
  18. Seifert B, Dítě P, Bureš J, et al. Dyspepsie horního typu. Doporučený diagnostický a léčebný postup pro všeobecné a praktické lékaře. [Internet]. [place unknown]: Společnost všeobecného lékařství ČLS JEP; 2008 [cited 2014 Apr 4]. 24 p. Available: http://www.svl.cz/Files/nastenka/page_4771/Version1/dyspepsie-horniho-typu.pdf.
  19. Olejárová M. Léčba bolesti u osteoartrózy. Interni Med. 2009; 11(12): 552-557.




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.